Effect of Δ9-tetrahydrocannabinol on experimental hypertension in rats

Varma, Daya R.; Goldbaum, D

doi:10.1111/j.2042-7158.1975.tb09406.x

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intriguing possibility of using cannabinoid ligands as antihypertensive agents was first considered more than 30 years ago (Archer, 1974;Adams et al, 1977;Birmingham, 1973;Crawford and Merritt, 1979;Varma and Goldbaum, 1975;Zaugg and Kyncl, 1983). However, initial enthusiasm was tempered by the inability to separate the neurobehavioral and cardiovascular effects of cannabinergic ligands and also by a report of the development of rapid tolerance to the hypotensive and bradycardic effects of THC (Adams et al, 1976).…”

Section: Role Of the Endocannabinergic System In Blood Pressure Regulmentioning

confidence: 99%

Blood pressure regulation by endocannabinoids and their receptors

2005

View full text Add to dashboard Cite

Cannabinoids and their endogenous and synthetic analogs exert powerful hypotensive and cardiodepressor effects by complex mechanisms involving direct and indirect effects on myocardium and vasculature. On the one hand, endocannabinoids and cannabinoid receptors have been implicated in the hypotensive state associated with hemorrhagic, endotoxic and cardiogenic shock, and advanced liver cirrhosis. On the other hand, there is emerging evidence suggesting that the endocannabinergic system plays an important role in the cardiovascular regulation in hypertension. This review is aimed to discuss the in vivo hypotensive and cardiodepressant effects of cannabinoids mediated by cannabinoid and TRPV 1 receptors, and focuses on the novel therapeutical strategies offered by targeting the endocannabinoid system in the treatment of hypertension.

show abstract

Section: Role Of the Endocannabinergic System In Blood Pressure Regulmentioning

confidence: 99%

Blood pressure regulation by endocannabinoids and their receptors

2005

View full text Add to dashboard Cite

show abstract

“…More than three decades ago, several studies explored the potential use of cannabinoids to treat hypertension (Birmingham, 1973;Archer, 1974;Varma and Goldbaum, 1975;Adams et al, 1977;Crawford and Merritt, 1979;Zaugg and Kyncl, 1983). Unfortunately, the initial high anticipation was tempered by a report of the development of rapid tolerance to the hypotensive and bradycardic effects of THC (Adams et al, 1976) and by the failure to separate the cardiovascular and neurobehavioral effects of cannabinoids.…”

Section: Cardiovascular and Respiratory Disordersmentioning

confidence: 99%

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Pacher

Bátkai

Kunos

2006

Pharmacological Reviews

1,840

1,819

View full text Add to dashboard Cite

“…Thus, in SHR tolerance to the hypotensive effect of Δ 9 ‐THC given at dose of 5 mg·kg −1 for 5 days or from 5 to 25 mg·kg −1 for 10 days developed within 2 and 9 days respectively (Nahas et al ., ). Interestingly, daily s.c. injection of Δ 9 ‐THC 1 or 2 mg·kg −1 for 3 to 5 weeks prevented the development of renal hypertension (Varma and Goldbaum, ).…”

Section: Effects Of Chronic Cannabinoid Administration On Cardiovascumentioning

confidence: 83%

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance

Malinowska

Toczek

Pędzińska-Betiuk

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

The endocannabinoid system is overactivated in arterial, pulmonary and portal hypertension. In this paper, we present limited clinical data concerning the role of cannabinoids in human hypertension including polymorphism of endocannabinoid system components. We underline differences between the acute cannabinoid administration and their potential hypotensive effect after chronic application in experimental hypertension. We discuss pleiotropic effects of cannabinoids on the cardiovascular system mediated via numerous neuronal and non‐neuronal mechanisms both in normotension and in hypertension. The final results are dependent on the model of hypertension, age, sex, the cannabinoid ligands used or the action via endocannabinoid metabolites. More experimental and clinical studies are needed to clarify the role of endocannabinoids in hypertension, not only in the search for new therapeutic strategies but also in the context of cardiovascular effects of cannabinoids and the steadily increasing legalization of cannabis use for recreational and medical purposes. Linked Articles This article is part of a themed section on 8 th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc

show abstract

Effect of Δ9-tetrahydrocannabinol on experimental hypertension in rats

Cited by 10 publications

References 8 publications

Blood pressure regulation by endocannabinoids and their receptors

Blood pressure regulation by endocannabinoids and their receptors

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance

Contact Info

Product

Resources

About